Atossa Therapeutics, Inc 8-K, filed Mar 13, 2023
Atossa Therapeutics, Inc. (ATOS)
8-K
2023-03-13
For: 2023-03-10
View Original
Added on
April 10, 2026
About this 8-K
Atossa Therapeutics, Inc filed this 8-K on March 13, 2023, reporting on events of March 10, 2023.
Items reported
- Item 8.01: Other events
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 13, 2023 (March 10, 2023 )
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(I.R.S. Employer
Identification No.) |
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (206 ) 588-0256
Not Applicable
Former name or former address, if changed since last report
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuance to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 8.01
|
Other Events. |
On March 13, 2023, Atossa Therapeutics, Inc. announced that it does not hold cash deposits or securities at Silicon Valley Bank ("SVB"). Media reports indicate that banking regulators have taken possession of SVB.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: March 13, 2023
|
Atossa Therapeutics, Inc.
|
||
|
By:
|
/s/ Kyle Guse
|
||
|
Kyle Guse
|
|||
|
Chief Financial Officer, General Counsel and Secretary
|
|||